EDGC Achieves California State Clinical Laboratory License, Expands Global Diagnostic Capabilities

INCHEON, South Korea - EntSun -- Eone-Diagnomics Genome Center (EDGC), a leading global genomics and precision medicine company headquartered in South Korea, is proud to announce that it has received official approval for the Clinical and Public Health Laboratory License from the California Department of Public Health (CDPH). This significant milestone enables EDGC's Incheon-based laboratory to legally accept and process clinical diagnostic samples from California and throughout the United States, under one of the most rigorous state-level regulatory frameworks in the country.

California is recognized for setting the highest standards for clinical laboratory operations in the U.S., and this approval reflects EDGC's ongoing commitment to excellence in laboratory medicine, regulatory compliance, and global clinical testing standards. With this license, EDGC becomes one of the few non-U.S. laboratories authorized to directly receive and test clinical samples from California, a state known for its stringent oversight in laboratory diagnostics.

More on EntSun News

• The Naturist World Just Shifted — NaturismRE Ignites a Global Resurgence
• $796,000 in Q2 Revenue Marks Highest Earnings to Date on 3 Trailing Quarters of Profitability in Multi-Billion Homebuilding Sector: Stock Symbol: IVDN
• Cybersecurity is THE Hot Market Sector; Revenues, Earnings & Profit matter; Only 33 Million Shares + a Huge Short Position Equal an Undervalued Stock
• Despite Global Calls for a Ban, US Child Psychiatry Pushes Electroshock for Kids
• Franco Polished Plaster Celebrates 35 Years of Bringing Walls to Life in the UK

"This license is not just a regulatory achievement—it's a validation of EDGC's quality, integrity, and leadership in global genomics," said Dr. Min Seob Lee, Founder and CEO of EDGC. "We are honored to serve physicians and patients in California and across the U.S., delivering advanced clinical testing in genomics and precision medicine."

EDGC currently provides CLIA-certified and CAP-accredited testing services to over 30 countries worldwide, offering a broad portfolio of high-precision diagnostics including:

• Non-Invasive Prenatal Testing (NIPT)
• Newborn Genetic Screening
• Oncology Liquid Biopsy
• EpiClock™ Biological Age and Longevity Testing
• Disease Risk Assessment
• Comprehensive Genetic Screening Panels

This California license enhances EDGC's ability to partner with U.S. hospitals, biotech firms, and research institutions, and accelerates its mission to make personalized genomic medicine accessible on a global scale.

More on EntSun News

• India's Home Textile Manufacturers See Rising Demand From Us Buyers, Enabled By rivexa
• Spartan & Guardians Partner with Guitar Legend Buckethead to Support Global Child Rescue Efforts
• Is the Entertainment Industry in Legal Tragedy: Was Nas's song The World is Yours taken literally
• Preliminary.online Introduces Short-Term Job-Readiness Courses with Employer-Verified Certifications
• Psychologist-Turned-Hermeticist Releases Modern Guide to the Seven Hermetic Principles

For more information or to inquire about EDGC's clinical services in the U.S. and internationally, please visit www.edgc.com.

About EDGC
Eone-Diagnomics Genome Center (EDGC) is a global leader in genomics and precision diagnostics, offering next-generation sequencing, bioinformatics, and AI-integrated testing platforms. With headquarters in Incheon, South Korea and global partnerships across Asia, Europe, and the U.S., EDGC is at the forefront of the DNA-driven revolution in healthcare.